Greater China Equity Long/Short Analyst

Eric Chen

Equity Bottom-Up

Focus Media Information Technology Co, Ltd. / Equity Bottom-Up

Focus Media Information Technology Co, Ltd.

<ul>
<li>Urbanization and brand premiumization are Focus Media's two long term structural drivers which will keep broadening its audience and advertiser base.</li>
<li>1Q23 results end a 5-quarter streak of profit decline and  mark the start of new profit cycle. This will usher in a meaningful stock re-rating if history is a guide.  </li>
<li>We expect at least 30% upside by the end of 2023 by applying 25x P/E (still at large discount to last profit cycle) on RMB4.9 billion net profit for 2023. </li>
</ul>


Urbanization and brand premiumization are Focus Media's two long term structural drivers which will keep broadening its audience and advertiser base.
1Q23 results end a 5-quarter streak of profit decline and  mark the start of new profit cycle. This will usher in a meaningful stock re-rating if history is a guide.  
We expect at least 30% upside by the end of 2023 by applying 25x P/E (still at large discount to last profit cycle) on RMB4.9 billion net profit for 2023. 


Focus Media (002027 CH): Light at the End of Tunnel

China/Asia TMT

Shawn Yang

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

<ul>
<li>We think the coffee price competition, mainly between Luckin and COTTI, is temporary, and will have little impact to Luckin’s gross margin. </li>
<li>We also think COTTI’s low pricing strategy is unsustainable, and its franchisees are keen for price hike.  </li>
<li>We maintain the stock as BUY and maintain TP at US$41.</li>
</ul>


We think the coffee price competition, mainly between Luckin and COTTI, is temporary, and will have little impact to Luckin’s gross margin. 
We also think COTTI’s low pricing strategy is unsustainable, and its franchisees are keen for price hike.  
We maintain the stock as BUY and maintain TP at US$41.


[Luckin Coffee Inc. (LKNCY US, BUY, TP US$41) ]: Temporary Price Competition Has No Impact on Margin

Thematic (Sector/Industry)

<ul>
<li>XPEV:  Xpeng unveils next - gen technology architecture ( + )</li>
<li>LKNCY: Hot weather supports new product sales, bodes well for 2Q23(+)</li>
<li>1211HK: Brazilian President Lula met with BYD CEO to promote opening of local EV plant (+)</li>
</ul>


XPEV:  Xpeng unveils next - gen technology architecture ( + )
LKNCY: Hot weather supports new product sales, bodes well for 2Q23(+)
1211HK: Brazilian President Lula met with BYD CEO to promote opening of local EV plant (+)


China TMT Update (Apr.18): XPEV/LKNCY/1211HK - Xpeng Unveils Next-Gen Technology Architecture

<ul>
<li>We expect Luckin to report 1Q23 revenue at 77.0% YoY to RMB4,257mn, non-GAAP operating margin and net margin are expected to increase 12.6ppt and 9.1ppt to 16.4% and 13.2%; </li>
<li>We think the current moderate competition can bring positive externality to coffee players, whereas it may hurt street tea shops; </li>
<li>We maintain the stock as BUY and raise TP by US$1 to US$41.</li>
</ul>


We expect Luckin to report 1Q23 revenue at 77.0% YoY to RMB4,257mn, non-GAAP operating margin and net margin are expected to increase 12.6ppt and 9.1ppt to 16.4% and 13.2%; 
We think the current moderate competition can bring positive externality to coffee players, whereas it may hurt street tea shops; 
We maintain the stock as BUY and raise TP by US$1 to US$41.


[Luckin Coffee Inc. (LKNCY US) TP Change]: Strong New Product Sales Driving Seasonality Rebound

<ul>
<li>LKNCY: Luckin Coffee launch new flavor Mint Coconut latte, and co-brand with Doraemon, but with no expectation to be the next blockbuster(+)</li>
<li>BGNE/9969HK:Abbview &amp; J&amp;J voluntarily withdrew two major indication of IMBRUVICA, a known positive to BeiGene but within our expectations (+)</li>
<li>ZLAB: GSK's court battle loss to AZ likely will not affect Zai Lab's royalty obligation on Zejula (/)</li>
</ul>


LKNCY: Luckin Coffee launch new flavor Mint Coconut latte, and co-brand with Doraemon, but with no expectation to be the next blockbuster(+)
BGNE/9969HK:Abbview &amp; J&amp;J voluntarily withdrew two major indication of IMBRUVICA, a known positive to BeiGene but within our expectations (+)
ZLAB: GSK's court battle loss to AZ likely will not affect Zai Lab's royalty obligation on Zejula (/)


China TMT Update(Apr.12/Pt2)-LKNCY/BGNE/9969HK/ZLAB - Abbview & J&J Voluntarily Withdrew

China

Luckin Coffee Inc. provides non-alcoholic beverages. The Company offers various types of coffee. Luckin Coffee serves customers in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Luckin Coffee (LKNCY US)

Focus Media (002027 CH): Light at the End of Tunnel

1Q23 results of Focus Media mark the start of a new profit cycle which will result in at least 30% upside for the stock by end 2023.

Eric Chen

[Luckin Coffee Inc. (LKNCY US, BUY, TP US$41) ]: Temporary Price Competition Has No Impact on Margin

We think the coffee price competition, mainly between Luckin and COTTI, is temporary, and will have little impact to Luckin’s gross margin.

Blue Lotus Research Institute

China TMT Update (Apr.18): XPEV/LKNCY/1211HK - Xpeng Unveils Next-Gen Technology Architecture

Xpeng unveils next - gen technology architecture; Hot weather supports new product sales, bodes well for 2Q23; Brazilian President Lula met with...

Blue Lotus Research Institute

[Luckin Coffee Inc. (LKNCY US) TP Change]: Strong New Product Sales Driving Seasonality Rebound

We expect Luckin to report 1Q23 revenue at 77.0% YoY to RMB4,257mn, non-GAAP operating margin and net margin are expected to increase 12.6ppt and...

Blue Lotus Research Institute

China TMT Update(Apr.12/Pt2)-LKNCY/BGNE/9969HK/ZLAB - Abbview & J&J Voluntarily Withdrew

Luckin Coffee launch new flavor Mint Coconut latte(+); Abbview & J&J voluntarily withdrew two major indication of IMBRUVICA(+); ZLAB: GSK's court...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)